Merck & Co., Inc.

MRK

Merck & Co., Inc.

MRK

Insider Sentiment (TTM):

Last Purchase:2025-02-06Last Sale:2026-02-12Shares Purchased (TTM):0Shares Sold (TTM):356,110

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:1,794,150,480Shares Outstanding:2,472,000,000Institutional Ownership Pct.:72.58%

Earnings Market Reaction:

Filing Date:2026-08-07Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Pharmaceutical Preparations

LLY JNJ ABBV ABT PFE VRTX

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Cash And Cash Equivalents At Carrying Value	6,849	5,327	14,565	18,169	8,007	8,629	13,242	14,593	11,304	5,579	6,841	8,605
Marketable Securities Current	292	375	0	45	615	599	447	0	50	40	252	168
Assets Current
Accounts Receivable Net Current	12,564	12,210	11,775	12,120	11,846	10,790	10,278	11,381	11,642	11,366	10,349	10,394
Assets Current	36,679	35,015	43,516	47,557	37,065	35,503	38,782	40,361	38,205	31,445	32,168	31,954
Inventory Net	6,207	6,479	6,658	6,444	6,601	6,196	6,109	6,244	6,469	6,510	6,358	6,131
Other Assets Current	10,767	10,624	10,518	10,779	9,996	9,289	8,706	8,143	8,740	7,950	8,368	6,656
Marketable Securities Noncurrent	1,222	1,105	956	1,117	774	616	463	575	357	280	252	1,306
Land	-	-	321	-	-	-	307	-	-	-	326	-
Buildings And Improvements Gross	-	-	17,983	-	-	-	16,360	-	-	-	14,966	-
Property Plant And Equipm…
Property Plant And Equipment Gross	-	-	47,230	-	-	-	42,934	-	-	-	41,317	-
Machinery And Equipment Gross	-	-	19,760	-	-	-	18,283	-	-	-	17,763	-
Construction In Progress Gross	-	-	9,166	-	-	-	7,984	-	-	-	8,262	-
Property Plant And Equipment Net	25,737	25,433	25,316	25,639	25,236	24,793	23,779	23,446	23,221	23,045	23,051	22,526
Goodwill	21,582	21,581	21,579	21,587	21,591	21,684	21,668	21,697	21,161	21,181	21,197	21,183
Intangible Assets Net Excluding Goodwill	24,978	25,745	26,681	15,313	15,193	15,758	16,370	17,010	16,984	17,572	18,011	19,199
Other Assets Noncurrent	19,604	19,806	18,818	18,333	17,664	16,768	16,044	14,443	12,702	12,326	11,996	10,559
Assets	129,802	128,685	136,866	129,546	117,523	115,122	117,106	117,532	112,630	105,849	106,675	106,727
Liabilities And Stockhold…
Debt Current	2,825	2,444	2,589	1,405	1,434	1,360	2,649	3,149	3,071	3,077	1,372	887
Accounts Payable Current	3,827	3,863	4,404	4,147	3,892	3,784	4,079	3,586	3,519	3,514	3,922	3,509
Liabilities Current
Liabilities Current	27,731	26,945	28,327	28,628	26,037	25,174	28,420	29,586	26,060	25,099	25,694	23,094
Other Liabilities Current	14,725	14,549	14,468	16,186	14,502	12,772	15,694	16,539	14,712	14,102	15,766	14,840
Accrued Income Taxes Current	4,224	3,946	4,726	4,848	4,156	5,181	3,914	4,330	2,777	2,398	2,649	1,981
Dividends Payable Current	2,130	2,143	2,140	2,042	2,053	2,077	2,084	1,982	1,981	2,008	1,985	1,877
Long Term Debt Noncurrent	51,081	46,673	46,750	39,969	33,968	33,484	34,462	34,982	34,717	31,142	33,683	33,972
Deferred Income Tax Liabilities Net	1,433	1,494	1,439	1,381	1,427	1,409	1,387	864	876	922	871	1,018
Other Liabilities Noncurrent	7,573	7,642	7,688	7,661	7,031	6,655	6,465	7,540	7,329	8,262	8,792	7,343
Common Stock Value	1,788	1,788	1,788	1,788	1,788	1,788	1,788	1,788	1,788	1,788	1,788	1,788
Additional Paid In Capital Common Stock	44,950	45,176	45,029	44,832	44,644	44,816	44,704	44,530	44,362	44,598	44,509	44,358
Stockholders Equity
Stockholders Equity	41,984	45,878	52,606	51,907	48,993	48,335	46,313	44,502	43,582	40,424	37,635	41,300
Retained Earnings Accumulated Deficit	63,269	66,721	73,075	72,231	68,477	66,097	63,069	61,384	60,187	56,697	53,895	57,082
Accumulated Other Comprehensive Income Loss Net Of…	-3,942	-4,060	-4,287	-5,202	-5,421	-4,965	-4,945	-5,371	-5,361	-5,274	-5,161	-4,916
Stockholders Equity Before Treasury Stock	106,065	109,625	115,605	113,649	109,488	107,736	104,616	102,331	100,976	97,809	95,031	98,312
Treasury Stock Common Value	64,132	63,747	62,999	61,799	60,495	59,401	58,303	57,829	57,394	57,445	57,450	57,066
Minority Interest	51	53	56	57	67	65	59	58	66	60	54	54
Liabilities And Stockholders Equity	129,802	128,685	136,866	129,546	117,523	115,122	117,106	117,532	112,630	105,849	106,675	106,727
Allowance For Doubtful Accounts Receivable Current	108	103	97	93	94	93	89	79	82	80	88	85
Inventory Noncurrent	6,381	6,195	5,681	5,412	4,882	4,556	4,193	3,995	3,456	3,413	3,348	3,151
Accumulated Depreciation Depletion And Amortizatio…	22,729	22,288	21,914	20,605	20,256	19,680	19,155	19,072	18,960	18,620	18,266	18,446
Common Stock Par Or Stated Value Per Share	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Common Stock Shares Authorized	6,500	6,500	6,500	6,500	6,500	6,500	6,500	6,500	6,500	6,500	6,500	6,500
Common Stock Shares Issued	3,577	3,577	3,577	3,577	3,577	3,577	3,577	3,577	3,577	3,577	3,577	3,577
Treasury Stock Common Shares	1,108	1,107	1,102	1,090	1,074	1,061	1,049	1,045	1,041	1,044	1,045	1,042

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	4.96%	14.57%	16.71%	-	-	-	-	-	-	-	-	-
2025	-6.73%	-4.00%	-2.91%	4.12%	-1.80%	9.36%	24.22%	27.61%	29.29%	-7.18%	-3.21%	-9.46%
2024	1.55%	3.13%	-0.77%	5.47%	1.91%	-6.80%	0.90%	-0.23%	-4.38%	2.72%	-13.95%	-16.09%
2023	-	-	-	-	-	-	-1.46%	4.93%	15.84%	-3.26%	-1.76%	2.47%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	1.32	1.30	1.54	1.66	1.42	1.41	1.36	1.36	1.47	1.25	1.25	1.38
Quick Ratio	1.10	1.06	1.30	1.44	1.17	1.16	1.15	1.15	1.22	0.99	1.00	1.12
Working Capital	8.95B	8.07B	15.19B	18.93B	11.03B	10.33B	10.36B	10.78B	12.15B	6.35B	6.47B	8.86B
Leverage & Debt
Debt to Equity	0.66	0.59	0.54	0.55	0.53	0.52	0.61	0.66	0.60	0.62	0.68	0.56
Debt Ratio	0.21	0.21	0.21	0.22	0.22	0.22	0.24	0.25	0.23	0.24	0.24	0.22
Efficiency & Turnover
Asset Turnover TTM	0.54	0.54	0.51	0.52	0.55	0.58	0.57	0.56	0.58	0.57	0.56	0.55
Days Sales Outstanding TTM	66.92	63.82	61.91	66.77	67.38	63.26	58.67	62.90	66.22	64.74	60.11	61.16
Receivables Turnover TTM	5.45	5.72	5.90	5.47	5.42	5.77	6.22	5.80	5.51	5.64	6.07	5.97
Per Share Metrics
Diluted EPS TTM	1.28	3.61	7.28	7.63	6.54	6.89	6.74	4.78	5.40	0.91	0.14	1.81
Free Cash Flow Per Share TTM	6.29	5.25	4.49	5.31	5.95	6.75	7.15	5.86	5.19	4.36	3.60	5.19
Dividend Per Share TTM	3.36	3.33	3.27	3.25	3.20	3.15	3.10	3.05	3.02	2.98	2.93	2.89
Margin Metrics
Gross Profit Margin TTM	72.97%	73.91%	74.80%	77.18%	76.60%	76.42%	76.32%	75.82%	75.25%	74.37%	73.17%	72.86%
Operating Profit Margin TTM	8.94%	17.68%	32.41%	33.96%	30.12%	31.55%	31.07%	21.72%	24.41%	6.37%	3.14%	12.56%
Net Profit Margin TTM	4.77%	13.59%	28.09%	29.66%	25.82%	27.30%	26.70%	19.23%	21.98%	3.76%	0.61%	7.79%
Growth Metrics
Net Revenue Growth (1Y)	4.64%	2.89%	1.31%	1.68%	1.82%	4.10%	6.74%	6.51%	7.15%	6.11%	1.40%	0.58%
Net Income Growth (1Y)	-80.68%	-48.80%	6.60%	56.78%	19.58%	656.44%	4,593.97%	163.10%	340.05%	-82.30%	-97.49%	-69.72%
EPS Growth (1Y)	-80.37%	-47.74%	7.87%	59.23%	20.72%	659.44%	4,603.24%	163.41%	340.92%	-82.27%	-97.49%	-69.77%
Valuation Metrics
P/E TTM	100.03	33.04	14.21	10.74	11.71	12.43	13.96	22.32	21.38	134.80	700.64	51.92
P/B TTM	7.56	6.44	4.93	3.94	3.92	4.49	5.16	6.09	6.74	7.69	6.80	5.81
P/S TTM	4.77	4.49	3.99	3.19	3.02	3.39	3.73	4.29	4.70	5.06	4.25	4.04
Market Cap	317.40B	295.23B	259.56B	204.63B	192.26B	216.97B	239.25B	271.16B	293.65B	310.99B	255.73B	239.76B
Enterprise Value	364.41B	338.95B	294.21B	227.75B	219.59B	243.08B	263.04B	294.60B	320.06B	339.54B	283.88B	265.95B
Calculated Values
Free Cash Flow TTM	15.53B	12.99B	11.23B	13.25B	14.92B	17.04B	18.10B	14.84B	13.15B	11.04B	9.14B	13.17B
Net Debt	47.02B	43.72B	34.65B	23.11B	27.33B	26.11B	23.79B	23.44B	26.42B	28.55B	28.15B	26.19B
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-02-12Sale

Owner: Guindo, Chirfi

Title: Chief Marketing Officer

Shares: 10,000

Price/Share: $121.46

Value: $1,214,600.00

Shares Owned: 60,615

Relationship: Officer

Ownership: Direct

2026-02-10Sale

Owner: Li, Dean Y

Title: Executive VP & President, MRL

Shares: 10,235

Price/Share: $117.52

Value: $1,202,817.20

Shares Owned: 92,035

Relationship: Officer

Ownership: Direct

2026-02-09Sale

Owner: Zachary, Jennifer

Title: EVP, General Counsel

Shares: 121,573

Price/Share: $119.15

Value: $14,485,422.95

Shares Owned: 68,916

Relationship: Officer

Ownership: Direct

2026-02-09Sale

Owner: Guindo, Chirfi

Title: Chief Marketing Officer

Shares: 10,000

Price/Share: $118.41

Value: $1,184,100.00

Shares Owned: 70,615

Relationship: Officer

Ownership: Direct

2026-02-06Sale

Owner: Deluca, Richard R.

Title: EVP&Pres, Merck Animal Heallth

Shares: 37,685

Price/Share: $120.92

Value: $4,556,870.20

Shares Owned: 160,174

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-02-12	Guindo, Chirfi	Officer	Chief Marketing Officer	Direct	Sale	10,000	121.46	$1,214,600.00	60,615	4
2026-02-10	Li, Dean Y	Officer	Executive VP & President, MRL	Direct	Sale	10,235	117.52	$1,202,817.20	92,035	4
2026-02-09	Zachary, Jennifer	Officer	EVP, General Counsel	Direct	Sale	121,573	119.15	$14,485,422.95	68,916	4
2026-02-09	Guindo, Chirfi	Officer	Chief Marketing Officer	Direct	Sale	10,000	118.41	$1,184,100.00	70,615	4
2026-02-06	Deluca, Richard R.	Officer	EVP&Pres, Merck Animal Heallth	Direct	Sale	37,685	120.92	$4,556,870.20	160,174	4
2026-02-06	Williams, David Michael	Officer	EVP,Chief Info&Digital Officer	Direct	Sale	5,000	121.91	$609,550.00	30,838	4
2026-02-06	Oosthuizen, Johannes Jaco…	Officer	President, U.S. Market	Direct	Sale	15,000	121.87	$1,828,050.00	21,197	4
2026-02-05	Guindo, Chirfi	Officer	Chief Marketing Officer	Direct	Sale	20,000	121.88	$2,437,600.00	80,615	4
2026-02-04	Smart, Dalton E. Iii	Officer	SVP Fin. - Global Controller	Direct	Sale	6,400	119.68	$765,952.00	8,205	4
2026-02-04	Davis, Robert M	Director,Officer	Chairman, CEO & President	Direct	Sale	47,434	117.86	$5,590,571.24	443,602	4
2026-02-04	Litchfield, Caroline	Officer	EVP & CFO	Direct	Sale	41,997	119.61	$5,023,261.17	90,192	4
2026-02-04	Li, Dean Y	Officer	Executive VP & President, MRL	Direct	Sale	15,087	118.77	$1,791,882.99	102,270	4
2025-11-10	Downing, Cristal N	Officer	Chief Comm. & Public Afrs Ofcr	Direct	Sale	7,085	87.00	$616,395.00	0	4
2025-11-03	Williams, David Michael	Officer	EVP,Chief Info&Digital Officer	Direct	Sale	8,614	83.59	$720,044.26	24,578	4
2025-04-25	Smart, Dalton E. Iii	Officer	SVP Fin. - Global Controller	Direct	Sale	4,262	82.76	$352,723.12	7,778	4
2025-02-19	Oosthuizen, Johannes Jaco…	Officer	President, U.S. Market	Direct	Sale	8,500	84.09	$714,765.00	30,705	4
2025-02-13	Williams, David Michael	Officer	EVP,Chief Info&Digital Officer	Direct	Sale	6,000	85.34	$512,040.00	24,123	4
2025-02-06	Downing, Cristal N	Officer	Chief Comm. & Public Afrs Ofcr	Direct	Sale	2,361	88.76	$209,562.36	7,085	4
2025-02-06	Thulin, Inge G	Director	-	Direct	Purchase	2,833	88.25	$249,999.90	2,933	4
2025-02-05	Baker, Douglas M Jr	Director	-	Direct	Purchase	15,000	88.50	$1,327,500.00	16,000	4
2024-02-14	Davis, Robert M	Director,Officer	Chairman, CEO & President	Direct	Sale	85,021	125.40	$10,661,633.40	348,327	4
2024-02-14	Litchfield, Caroline	Officer	EVP & CFO	Direct	Sale	38,291	125.50	$4,805,520.50	50,908	4
2024-02-13	Romanelli, Joseph	Officer	President, Human Health Int?l	Direct	Sale	1,000	124.89	$124,890.00	19,569	4
2024-02-09	Li, Dean Y	Officer	Executive VP & President, MRL	Direct	Sale	14,702	125.50	$1,845,101.00	46,242	4
2024-02-07	Williams, David Michael	Officer	EVP,Chief Info&Digital Officer	Direct	Sale	1,451	127.57	$185,104.07	19,812	4
2024-02-02	Zachary, Jennifer	Officer	EVP, General Counsel	Direct	Sale	49,499	126.97	$6,284,888.03	29,058	4
2024-02-02	Oosthuizen, Johannes Jaco…	Officer	President, U.S. Market	Direct	Sale	18,959	127.18	$2,411,205.62	23,327	4
2024-02-02	Mizell, Steven	Officer	EVP, Chief HR Officer	Direct	Sale	50,694	126.65	$6,420,395.10	23,619	4
2023-11-09	Oosthuizen, Johannes Jaco…	Officer	President, U.S. Market	Direct	Sale	2,081	102.38	$213,052.78	18,191	4
2023-11-08	Deluca, Richard R.	Officer	EVP&Pres, Merck Animal Heallth	Direct	Sale	43,823	105.03	$4,602,729.69	111,764	4
2023-08-14	Mizell, Steven	Officer	EVP, Chief HR Officer	Direct	Sale	4,250	109.01	$463,292.50	22,935	4
2023-08-03	Mizell, Steven	Officer	EVP, Chief HR Officer	Direct	Sale	4,500	105.49	$474,705.00	27,185	4
2023-08-02	Romanelli, Joseph	Officer	President, Human Health Int?l	Direct	Sale	30	107.37	$3,221.10	20,569	4
2023-05-04	Karachun, Rita A	Officer	Sr. VP Fince-Global Controller	Direct	Sale	15,875	117.53	$1,865,788.75	45,710	4
2023-05-04	Zachary, Jennifer	Officer	EVP, General Counsel	Direct	Sale	19,141	117.59	$2,250,790.19	35,128	4
2023-05-03	Mizell, Steven	Officer	EVP, Chief HR Officer	Direct	Sale	53,400	119.01	$6,355,134.00	31,685	4
2023-05-02	Williams, David Michael	Officer	EVP,Chief Info&Digital Officer	Direct	Sale	7,509	116.82	$877,201.38	11,059	4
2023-05-01	Deluca, Richard R.	Officer	EVP&Pres, Merck Animal Heallth	Direct	Sale	75,436	116.03	$8,752,839.08	154,493	4
2023-04-28	Davis, Robert M	Director,Officer	Chairman, CEO & President	Direct	Sale	143,329	114.93	$16,472,801.97	271,817	4
2023-04-13	Chattopadhyay, Sanat	Officer	Exe V-P & Pres. MMD	Direct	Sale	134,055	115.06	$15,424,368.30	0	4
2023-03-24	Romanelli, Joseph	Officer	President, Human Health Int?l	Direct	Sale	35	104.65	$3,662.75	20,596	4
2023-02-15	Romanelli, Joseph	Officer	President, Human Health Int?l	Direct	Sale	5,000	108.22	$541,100.00	20,284	4
2023-02-13	Mizell, Steven	Officer	EVP, Chief HR Officer	Direct	Sale	1,815	109.10	$198,016.50	33,085	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

72.58%

Inst. Shares: 1,794,150,480

Shares Outstanding: 2,472,000,000

2025-12-31

74.32%

Inst. Shares: 1,859,406,460

Shares Outstanding: 2,502,000,000

2025-09-30

72.65%

Inst. Shares: 1,812,661,845

Shares Outstanding: 2,495,000,000

2025-06-30

74.05%

Inst. Shares: 1,858,717,074

Shares Outstanding: 2,510,000,000

2025-03-31

72.79%

Inst. Shares: 1,836,499,705

Shares Outstanding: 2,523,000,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	1,794,150,480	2,472,000,000	72.58%
2025-12-31	1,859,406,460	2,502,000,000	74.32%
2025-09-30	1,812,661,845	2,495,000,000	72.65%
2025-06-30	1,858,717,074	2,510,000,000	74.05%
2025-03-31	1,836,499,705	2,523,000,000	72.79%
2024-12-31	1,866,834,060	2,532,000,000	73.73%
2024-09-30	1,809,521,338	2,534,000,000	71.41%
2024-06-30	1,832,709,573	2,534,000,000	72.32%
2024-03-31	1,766,069,216	2,533,000,000	69.72%
2023-12-31	1,787,254,209	2,537,000,000	70.45%
2023-09-30	1,713,024,586	2,537,000,000	67.52%
2023-06-30	1,706,478,703	2,539,000,000	67.21%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Merck & Co., Inc. (MRK) — SEC Financial Statements & Analysis

Merck & Co., Inc. (MRK) is a pharmaceutical preparations company, incorporated in NJ. Merck & Co., Inc. trades on NYSE as: MRK. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Merck & Co., Inc. reported a 4.64% year-over-year revenue growth, a Gross Profit Margin of 72.97% (TTM), a Debt-to-Equity ratio of 0.66x, a Price-to-Sales (P/S) ratio of 4.77x (TTM), a Price-to-Book (P/B) ratio of 7.56 (TTM), at a market cap of $317.39B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 4.64%
Gross Profit Margin TTM: 72.97%
Debt To Equity: 0.66x
P/S TTM: 4.77x
P/B TTM: 7.56
Market Cap: $317.39B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Merck & Co., Inc. in?

Merck & Co., Inc. (MRK) operates in the Pharmaceutical Preparations industry.

What is MRK's market cap?

Merck & Co., Inc. (MRK) has a market capitalization of $317.39B as of 2026-06-30.

What is MRK's P/E ratio?

Merck & Co., Inc. (MRK)'s trailing twelve month P/E ratio is 100.03x as of 2026-06-30.

What exchange does MRK trade on?

Merck & Co., Inc. (MRK) trades on the NYSE.

Where is Merck & Co., Inc. incorporated?

Merck & Co., Inc. is incorporated in NJ.

Merck & Co., Inc. (MRK) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.